Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma

Atherosclerosis

Volumn 200, Issue 1, 2008, Pages 37-44

  Vinh, Antony ^a   Widdop, Robert E ^a   Chai, Siew Yeen ^b   Gaspari, Tracey A ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin IV; AT2 receptor; AT4 receptor; Endothelial dysfunction; Nitric oxide bioavailability; Superoxide

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN 4 RECEPTOR; ANGIOTENSIN 4 RECEPTOR ANTAGONIST; ANGIOTENSIN II [3-8]; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; DIVALINAL ANGIOTENSIN IV; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROETHIDINE; NITRIC OXIDE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; AUTORADIOGRAPHY; BIOAVAILABILITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENDOTHELIAL DYSFUNCTION; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOREACTIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STAINING; VASCULAR ENDOTHELIUM; VASODILATATION; WILD TYPE;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; BLOOD PRESSURE; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; IMIDAZOLES; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SUPEROXIDES; UP-REGULATION;

EID: 49749139399     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.12.042     Document Type: Article

References (30)

1. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 (2000) 840-844
2. Luscher T.F., and Barton M. Biology of the endothelium. Clin Cardiol 20 (1997) II-3-10
3. Gimbrone Jr. M.A. Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 75 (1995) 67B-70B
4. Cai H., Griendling K.K., and Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24 (2003) 471-478
5. Ruiz-Ortega M., Lorenzo O., Ruperez M., et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 38 (2001) 1382-1387
6. Suzuki Y., Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., and Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 35 (2003) 881-900
7. Touyz R.M. Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz J Med Biol Res 37 (2004) 1263-1273
8. Vinh A., Widdop R.E., Drummond G.R., and Gaspari T.A. Chronic angiotensin IV treatment reverses endothelial dysfunction in apoe-deficient mice. Cardiovasc Res 77 (2008) 178-187
9. Zulli A., Burrell L.M., Widdop R.E., Black M.J., Buxton B.F., and Hare D.L. Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. J Histochem Cytochem 54 (2006) 147-150
10. Daugherty A., Rateri D.L., Lu H., Inagami T., and Cassis L.A. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110 (2004) 3849-3857
11. Carey R.M., and Siragy H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24 (2003) 261-271
12. Santos R.A., Campagnole-Santos M.J., and Andrade S.P. Angiotensin-(1-7): an update. Regul Pept 91 (2000) 45-62
13. Santos R.A.S., Simoes e Silva A.C., Maric C., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100 (2003) 8258-8263
14. Walters P.E., Gaspari T.A., and Widdop R.E. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45 (2005) 960-966
15. Wright J.W., Krebs L.T., Stobb J.W., and Harding J.W. The angiotensin IV system: functional implications. Front Neuroendocrinol 16 (1995) 23-52
16. Albiston A.L., McDowall S.G., Matsacos D., et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276 (2001) 48623-48626
17. Daugherty A., and Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 14 (2004) 117-120
18. Vinh A., Gaspari T.A., Liu H.B., Dousha L.F., Widdop R.E., and Dear A.E. A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. J Vasc Res 45 (2008) 143-152
19. Moeller I., Clune E.F., Fennessy P.A., et al. Upregulation of AT4 receptor levels in carotid arteries following balloon injury. Regul Pept 83 (1999) 25-30
20. Reddick R.L., Zhang S.H., and Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb Vasc Biol 14 (1994) 141-147
21. Daugherty A., Manning M.W., and Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105 (2000) 1605-1612
22. Daugherty A., Manning M.W., and Cassis L.A. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 134 (2001) 865-870
23. Deng G.G., Martin-McNulty B., Sukovich D.A., et al. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res 92 (2003) 510-517
24. Iwai M., Chen R., Li Z., et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 112 (2005) 1636-1643
25. Sales V.L., Sukhova G.K., Lopez-Ilasaca M.A., Libby P., Dzau V.J., and Pratt R.E. Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation 112 (2005) 3328-3336
26. Hamilton C.A., Brosnan M.J., Al-Benna S., Berg G., and Dominiczak A.F. NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 40 (2002) 755-762
27. Miller F.J., Gutterman D.D., Rios C.D., Heistad D.D., and Davidson B.L. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82 (1998) 1298-1305
28. Mugge A., Elwell J.H., Peterson T.E., Hofmeyer T.G., Heistad D.D., and Harrison D.G. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 69 (1991) 1293-1300
29. Bonetti P.O., Lerman L.O., and Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23 (2003) 168-175
30. Esteban V., Ruperez M., Sanchez-Lopez E., et al. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 96 (2005) 965-973